Syndax Pharmaceuticals, Inc.
SNDXNext catalyst
SNDX-5613
Acute Myeloid Leukemia
Get an email about SNDX's next catalysts
Track Syndax Pharmaceuticals (SNDX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 1 past
SNDX-5613 Phase 2 Est. Readout
Estimated primary completion for SNDX-5613 trial (NCT05360160) in Acute Myeloid Leukemia. Topline data typically follows completion by weeks to months.
SourceRevumenib Phase 2 Est. Readout
Estimated primary completion for Revumenib trial (NCT06284486) in Acute Myeloid Leukemia. Topline data typically follows completion by weeks to months.
SourceEntinostat Phase 2 Est. Readout
Estimated primary completion for Entinostat trial (NCT03179930) in Lymphoma. Topline data typically follows completion by weeks to months.
SourceHow SNDX's past catalysts played out
Market Overview
Stock performance and key metrics
Intensive Chemotherapy Regimen
Acute Myeloid Leukemias
Revumenib
Colorectal Cancer
Aromatase Inhibitor (AI) Therapy
ER+ Breast Cancer
Axatilimab
Chronic Graft-versus-host-disease
SNDX-5613
Acute Myeloid Leukemia
cobicistat
Acute Myeloid Leukemia
ASTX727
Acute Myeloid Leukemia
entinostat
Non-Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Intensive Chemotherapy Regimen | Phase 3 | Acute Myeloid Leukemias | - | - |
Revumenib | Phase 3 | Colorectal Cancer | - | - |
Aromatase Inhibitor (AI) Therapy | Phase 2 | ER+ Breast Cancer | - | - |
Axatilimab | Phase 2 | Chronic Graft-versus-host-disease | - | - |
SNDX-5613 | Phase 2 | Acute Myeloid Leukemia | - | - |
cobicistat | Phase 2 | Acute Myeloid Leukemia | - | - |
ASTX727 | Phase 2 | Acute Myeloid Leukemia | - | - |
entinostat | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Syndax Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Syndax Pharmaceuticals, Inc.'s (SNDX) pipeline across Phase 3, Phase 2. Its lead program is Revumenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Syndax Pharmaceuticals, Inc.'s next FDA catalyst?→
Syndax Pharmaceuticals, Inc.'s (SNDX) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SNDX biotech catalysts?→
Add SNDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Syndax Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
